How Long Will You — Stay on Bevacizumab?

For most cancers, there is no preset number. NCCN and ESMO guidelines recommend continuing until progression or unacceptable toxicity, which means the total number of cycles is determined by your scan results and how your body responds. If your regimen includes a defined maintenance phase — which applies to some cancer types — your oncologist will tell you the planned length at the beginning. Ask directly: 'Is there a planned number of cycles for my regimen, or do we continue until something stops us?' You are entitled to a clear answer to that question.

No. Bevacizumab always stops at some point — because the cancer stops responding, because a side effect makes it unsafe to continue, or because a planned maintenance phase ends. 'Indefinite' is not the same as 'forever': it means the end point is set by your disease and your response rather than by a fixed date. Most people are not on bevacizumab for years without any review or change. The length varies considerably by cancer type and by how the individual responds.

Stable disease — where the cancer has not grown significantly — is generally a reason to continue bevacizumab, not to stop it. The aim of the treatment is to prevent the cancer from growing, so stable disease is a sign it is doing its job. Your oncologist will explain what stable disease means in the context of your specific cancer, because the significance varies by cancer type and by how the disease was behaving before treatment began.

It often can, if the break was taken for a manageable side effect that has now resolved. Your oncologist will assess the reason for the break, whether the relevant problem has recovered, and what your current scan shows before making that decision. A restart is less likely — and often not advised — after a serious event such as a bowel perforation or a major bleed. Ask your oncologist to be specific about whether restarting is an option in your case and what the conditions for it would be.

The events that typically end bevacizumab permanently rather than prompting a pause are a bowel or stomach perforation, a serious arterial event such as a stroke or heart attack, a significant internal bleed, or nephrotic syndrome — heavy protein loss indicating serious kidney damage. These are uncommon, and your team monitors specifically for the early warning signs of each at every visit. If any of them occurs, your oncologist will discuss what the next treatment option is for your cancer.

NCCN, ASCO and ESMO guidance for bevacizumab includes blood pressure measurement before each infusion, urine protein monitoring at regular intervals, and scan-based response assessment throughout treatment. If those checks are happening and you are getting a clear explanation of what the results mean after each review, your team is following the standard approach. If you are unsure what is being tested and why, ask your oncologist or nurse to walk you through what is measured at each visit and what result would change the plan.